Clinical Trial: NRG EAY191-N4

NRG EAY191-N4

Status: Open

A Randomized Trial of Selumetinib and Olaparib or Selumetinib Alone in Patients with Recurrent or Persistent RAS Pathway Mutant Ovarian and Endometrial Cancers: A ComboMATCH Treatment Tria

(See required screening study ECOG-ACRIN EAY191)